CN108517315A - Anti-human IgM monoclonal antibody, its hybridoma cell strain and application - Google Patents
Anti-human IgM monoclonal antibody, its hybridoma cell strain and application Download PDFInfo
- Publication number
- CN108517315A CN108517315A CN201810296837.3A CN201810296837A CN108517315A CN 108517315 A CN108517315 A CN 108517315A CN 201810296837 A CN201810296837 A CN 201810296837A CN 108517315 A CN108517315 A CN 108517315A
- Authority
- CN
- China
- Prior art keywords
- kit
- antibody
- monoclonal antibody
- igm
- hybridoma cell
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/42—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins
- C07K16/4283—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins against an allotypic or isotypic determinant on Ig
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
- G01N33/56983—Viruses
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/577—Immunoassay; Biospecific binding assay; Materials therefor involving monoclonal antibodies binding reaction mechanisms characterised by the use of monoclonal antibodies; monoclonal antibodies per se are classified with their corresponding antigens
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6854—Immunoglobulins
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Immunology (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Urology & Nephrology (AREA)
- Biomedical Technology (AREA)
- Hematology (AREA)
- General Health & Medical Sciences (AREA)
- Biochemistry (AREA)
- Medicinal Chemistry (AREA)
- Food Science & Technology (AREA)
- Pathology (AREA)
- Cell Biology (AREA)
- Biotechnology (AREA)
- Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- Microbiology (AREA)
- General Physics & Mathematics (AREA)
- Virology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Organic Chemistry (AREA)
- Tropical Medicine & Parasitology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Abstract
The present invention relates to hybridoma cell strain and its secreted monoclonal antibody, the antibody can be specifically bound with people IgM, and can be used for the vitro detection of people IgM, be especially suitable for the early diagnosis of rubella virus infection.The invention further relates to the kits for including the hybridoma cell strain or monoclonal antibody.
Description
Technical field
The present invention relates to a kind of monoclonal antibody, more particularly to a kind of monoclonal antibody of anti-human IgM.
Background technology
Immune diagnostic reagent is one of main Types of external diagnosis reagent.Its spy being combined with each other using antigen and antibody
The opposite sex reacts to carry out qualitative or quantitative diagnosis, either technology or market, and such reagent is in current all diagnostic reagents
It is with fastest developing speed in product.
After cause pathogeny imcrobe infection human body, IgM types antibody generates at first during stimulating induction body fluid immune response,
The early diagnosis of infectious diseases is the premise for carrying out early stage, effectively treating, especially for onset urgency, the dangerous infection of the state of an illness
Property disease, early diagnosis is particularly important, since body occurs at first after infection antibody is IgM type antibody, therefore detects morbidity just
Specific IgM antibodies have great importance in clinic early diagnoses in phase blood samples of patients.
In recent years, the research that there are some about anti-human IgM monoclonal antibody, such as patent document WO 2010026758A1
In disclose a kind of anti-human IgM monoclonal antibody, which aims to solve the problem that the low problem of polyclonal antibody specificity, and resit an exam
It has examined the property being aggregated between monoclonal antibody induction people IgM and has demonstrated it and inhibited the effect of non-specific responding, but do not closed
Note in the anti-human IgM monoclonal antibody be used for external diagnosis reagent when systematicness evaluation (as, antibody titer, cross reactivity,
Stability, detection sensitivity and specificity etc.), thus, it is indefinite that whether which, which is suitable for preparing external diagnosis reagent,.
In another example the anti-human IgM monoclonal antibody of Xiamen wave life biology is the anti-human IgM monoclonal antibody of common commercialization,
But its stability is not good enough, to Shortcomings when for immunodiagnosis antibody.
In fact, it is a complicated process that screening, which is used to prepare the monoclonal antibody of external diagnosis reagent, first have to obtain
Good antigen is obtained, to prepare enough antibody, the evaluation of system is then carried out to antibody, is obtained with clinical correlation
Candidate antibodies are redeveloped into detection reagent.Wherein, antibody titer, cross reactivity, stability and clinical effectiveness etc. are important
Factor of evaluation, as antibody titer height reflect under a certain concentration with antigen reactive minimum titre, titre more low liter more
It is high；Antibody cross reaction can influence the specificity of the antibody；The stability of antibody will have a direct impact on the reliability of final result,
And the poor antibody of stability requires higher to preservation condition, operating condition, to reduce its practicality as diagnostic reagent
The reliability of property and result, and inevitably cause the rising of cost；Clinical test is then used for illustrating that antibody is diagnosing certain
Effect when specified disease.
Therefore, in order to diagnose the application of aspect in vitro, urgent need systemic evaluation result in this field is preferable, and is suitable for especially
The monoclonal antibody of the early diagnosis of pathogen infection.
Invention content
The object of the present invention is to provide a kind of anti-human IgM monoclonal antibody, the hybridoma cell strain for secreting the antibody, containing upper
State the kit and their purposes in detecting people IgM of monoclonal antibody or hybridoma cell strain.It is evaluated by systematicness,
The antibody has preferable performance in all respects, and external diagnosis reagent case is used to prepare to be suitable as immune diagnostic reagent,
It is especially suitable for preparing rubella virus early diagnosis kit.
For this purpose, present inventor has performed numerous studies, mouse is immunized by people IgM, through limiting dilution after cell fusion
Method clone at least 4 times, until reaching monoclonal, screened from obtained numerous clones 1 plant can stably excreting antibody it is novel
Hybridoma cell strain (Hybridoma) IgM-5, and be preserved in China typical culture collection on March 8th, 2018
The heart, the Chinese Wuhan Wuhan Universitys, deposit number are CCTCC NO:C201847, so as to complete the present invention.
In the first aspect, the present invention provides a kind of hybridoma cell strain, it is preserved in China typical culture collection
Center, deposit number are CCTCC NO:C201847.
In the second aspect, the present invention provides a kind of monoclonal antibody, the monoclonal antibody can be special with people IgM
The opposite sex combines.
In one embodiment, the monoclonal antibody is not combined with human IgG, mouse IgG, rabbit igg or ox IgG.
In another embodiment, the middle titer of the monoclonal antibody is 138900 and in multigelation, long-term
It preserves, there is more preferably stability and reliability under thermal acceleration mal-condition.
In one preferred embodiment, the monoclonal antibody is by the anti-of the hybridoma cell strain secretion of the present invention
Body.
In terms of third, the present invention provides a kind of kit, the kit includes the hybridoma of the present invention
Strain or monoclonal antibody.
In a specific embodiment, the kit is colloidal gold immunoassay kit, chemical luminescence reagent kit, radiation
Immune reagent kit, enzyme linked immunological kit or fluorescence immunoassay kit.
In one preferred embodiment, the kit is enzyme linked immunological kit.
In another embodiment, the kit is micro-fluid chip.
At the 4th aspect, the use of the hybridoma cell strain or monoclonal antibody of the present invention in reagent preparation box is provided
On the way.
In one embodiment, the kit is the kit based on immune detection, it is preferred that the kit is
Colloidal gold immunoassay kit, chemical luminescence reagent kit, radioimmunoassay kitss, enzyme linked immunological kit or fluorescence immunoassay reagent
Box.
In one preferred embodiment, the kit is enzyme linked immunological kit.
In another embodiment, the kit is micro-fluid chip, it is preferred that the micro-fluid chip is based on
Immune detection.
In one embodiment, the kit is for detecting people IgM.
In one preferred embodiment, the people IgM is the people IgM generated at pathogen infection initial stage.
In a specific embodiment, the cause of disease is rubella virus.
In addition, the monoclonal antibody for additionally providing hybridoma cell strain of the invention or the present invention is being prepared for rubella
Purposes in the kit of poison diagnosis, is preferred for the kit of rubella virus early diagnosis.
The advantageous effect of the monoclonal antibody of the present invention is that first, antibody titer is more usually used than in in-vitro diagnosis
At least high an order of magnitude of commercially available human IgM antibody, have more preferably immune effect；Secondly, antibody of the invention and human IgG,
Mouse IgG, rabbit igg, ox IgG no cross reactions have good specific binding capacity；Again, have than commercially available people IgM
Antibody is more preferably for a long time and thermal stability, that is to say, that extends service life and can receive condition of storage and the behaviour of relative loose
Make condition, to which cost be greatly saved；Finally, clinical trial shows that the monoclonal antibody of the present invention can be used for preparing rubella
The enzyme linked immunological kit of malicious IgM antibody detection, detection sensitivity detect specificity up to 100% up to 100%.
That is, the monoclonal antibody of the present invention is more in antibody titer, cross reactivity, stability and detection result etc.
A aspect has shown good performance, to can be used for in-vitro diagnosis and comprehensive through systematicness evaluation the present invention provides a kind of
Conjunction ability anti-human IgM monoclonal antibody outstanding.
Description of the drawings
Fig. 1 shows the SDS-PAGE electrophoresis of the antibody IgM-Ab5 of the present invention；
Fig. 2 shows the antibody IgM-Ab5 of the present invention and the antibody titer of two kinds of commercialization anti-human IgM antibodies to measure knot
Fruit, wherein abscissa are Log (extension rate), ordinate OD450。
Specific implementation mode
Below in conjunction with specific implementation mode and embodiment, it is specifically described the present invention, advantages of the present invention and various effects
It thus will clearly present.It will be understood by those skilled in the art that these specific implementation modes and embodiment are for illustrating
The present invention is not intended to limit the present invention.
Throughout the specification, unless otherwise specified, terms used herein are interpreted as usual in this field
Used meaning.Therefore, unless otherwise defined, all technical and scientific terms used herein has and is led with belonging to the present invention
The identical meaning of general understanding of field technique personnel.If there are contradiction, this specification is preferential.
Antibody
As it is used herein, term " antibody " refers to immunoglobulin molecules, including but not limited to chimeric antibody, Ren Yuan
Change antibody, human antibody, CDR grafted antibody and antibody construct, such as scFv (scFv) or antibody fusion protein；In addition,
Further relate to recombination ground or the synthetically antibody of generation/synthesis.
In a preferred embodiment, antibody refers to being produced from deposit number as CCTCC NO:The hybridoma of C201847
The antibody of cell strain.
" antibody fragment " generally includes the antigen binding domain of parental generation antibody, light chain and/or heavy chain variable region, one or more
At least part of (such as six) CDR retains at least certain binding specificity of parental generation antibody.Particularly, herein
Parental generation antibody refers to being produced from deposit number as CCTCC NO:The antibody of the hybridoma cell strain of C201847.Antibody fragment
Example includes but not limited to Fab, Fab', F (ab') 2 and Fv segments；Homodimer；Linear antibodies；Single-chain antibody molecules, example
Such as, sc-Fv；And the multi-specificity antibody formed by antibody fragment.In general, when based on mole come expression activity, segment is protected
It is left to the few 50% combination activity to people IgM.Preferably compared with parental generation antibody, segment retain at least 60%, 70%,
80%, 90%, the 95% or 100% combination activity to people IgM.
Preferably, antibody fragment refers to antigen binding domain, light chain and the heavy chain variable region or six CDR of antibody.
" antibody derivatives " refer to may include antibody conserved amino acid substitutes (be known as " conservative variant "), its life
Object activity does not change substantially compared with parental generation antibody.
The present invention provides the monoclonal in form of antibody.
As used herein, term " monoclonal antibody " refers to the antibody for being obtained from the substantially group of allo-antibody,
That is, except it is possible can be in addition to a small amount of existing abiogenous mutation, it is identical to constitute the individual antibody of group.For list
Antigen site, monoclonal antibody are high specials.Monoclonal antibody is advantageous, because they can pass through hybridoma
Strain culture obtains, and is not polluted by other immunoglobulins substantially.
Kit
Diversified forms can be used in the detection kit of the present invention, for example, test paper, the test containing reagent needed for various tests
Box, micro-fluid chip etc. can manufacture kit according to standard step well known by persons skilled in the art.
The present invention kit may include as needed container, chip, operation instructions, buffer, immune auxiliaries and/or
For carrying out diagnosing/detecting required other materials, structure and/or reagent.
The kit of the present invention is illustrated using for enzyme-linked immunosorbent assay in embodiment, but should not be construed as this hair
Bright kit is only limitted to enzyme-linked immunosorbent assay.
The kit of the present invention includes being produced from deposit number as CCTCC NO:The hybridoma cell strain of C201847 resists
Body can be existed in such a way that this field is conventional, for example, being present in container with dissolving or dried forms, be coated on solid phase
On carrier (for example, film, plate, pearl, particle (such as magnetic particle)), it is present in the chamber of chip with dissolving or dried forms, but
The invention is not limited thereto.
Since objective factors, the kits such as transport and place to use generally require to be suitble to be showed in all kinds of complex environments
Field detecting, therefore, the stability of raw material are one of an important factor for restricting kit results.Shown in following article embodiment 9
, more conventional IgM antibody possesses more under extreme conditions as the raw material of enzyme linked immunological kit by antibody IgM-Ab5 of the invention
Good stability, to make the result reliability of kit enhance and in a disguised form reduce cost.
The antibody of the present invention can be used with the concentration of 0.1~10 μ g/ml, preferably 1~5 μ g/ml, more preferably 1.5 μ
g/ml。
It is used to carry out diagnosing/detecting required other materials in the kit of the present invention to include but not limited to remove the present invention
Antibody outside other anti-human IgM antibodies, the antigen that is combined with human IgM antibody and/or people IgM.Above-mentioned other materials can be with
The mode of this field routine exists, for example, be present in container with dissolving or dried forms, be coated on solid phase carrier (for example,
Film, plate, pearl, particle (such as magnetic particle)), it is present in the chamber of chip with dissolving or dried forms, but the present invention is not limited to
This.
For carrying out diagnosing/detecting required other structures including but not limited to for sampling knot in the kit of the present invention
Structure, the structure for carrying out contrast structure and/or for observing detection process or result.
It is used to diagnose/detect other required reagents in the kit of the present invention to include but not limited to, detergent, show
Toner and/or terminator.
In one embodiment, the antibody in kit of the present invention detectably marks.Ability can be used
Any marker and labeling method known to field technique personnel.For example, the marker that can be used in the present invention includes enzyme, puts
Injectivity isotope, colloidal metal, fluorescent chemicals, chemiluminescence compound and bioluminescent compound, but the present invention is not limited to
This.
Common marker may include enzyme (such as horseradish peroxidase, beta galactosidase, alkaline phosphatase), radiation
Property isotope is (such as32P or125I) etc., biotin, digoxin, colloidal metal (such as colloidal gold), fluorescent dye (such as fluorescein, sieve
Red bright, texas Red etc.), chemiluminescence compound or bioluminescent compound (such as dioxetane, luminol or acridine
Deng).Any markers step well-known in the art can be used, such as enzyme or the covalent coupling of biotin group, iodate, phosphorus
Acidification, biotinylation etc..
In some embodiments, for diagnose/detect in required other materials it is one or more can also
Detectably mark.
In one preferred embodiment, kit of the invention is the kit early diagnosed for cause of disease.
Purposes
The anti-human IgM antibodies or hybridoma cell strain of the present invention can be used for relevant any with the specific reaction of people IgM
Purpose.Preferably, antibody of the invention or hybridoma cell strain can be used for detecting people IgM.
The antibody or hybridoma cell strain of the present invention can be detected the biological sample from the mankind.
As used herein, " biological sample " refers to sperm, lymph, serum, blood plasma, urine, synovia or spinal fluid.
In preferred embodiment, biological sample refers to blood, serum or blood plasma.
Preferably, using the biological sample for the early stage for coming from people.
The method of immunoassays can be used quantitative or the presence of qualitative detection people IgM, the immunoassays generally include
Biological sample is incubated together with the other materials needed for the antibody of the present invention and/or detection or is contacted successively, and by a variety of
The antibody that technology detection well known in the art combines.
Detection method includes but not limited to autoradiograph, fluorescence microscopy, enzymatic reaction directly or indirectly, puts
Injectivity isotope method or non radioactive isotope method etc..These methods especially include western blot, overlapping measures, RIA (is put
Penetrate immunoassays) and IRMA (immune radiating immunoassays), GIA (colloid gold immune measurement), EIA (enzyme immunoassay (EIA)), ELISA
(enzyme linked immunosorbent assay (ELISA)), FIA (fluorescence immunoassay) and CLIA (chemiluminescence immunoassay).
The people IgM that anti-human IgM monoclonal antibody can be generated with various pathogen infections is combined, but is preparing in-vitro diagnosis examination
When agent, since detection architecture is different or the nature difference of antibody itself, diagnosis effect inevitably can difference.It is real in following article
It applies shown in example 8, for antibody of the invention in IgM caused by detecting rubella virus (RV), effect is commercially available better than common at present
Detection kit.
Therefore, in one preferred embodiment, antibody of the invention or hybridoma cell strain are particularly suitable for detecting
The people IgM that rubella virus infection initial stage generates, to diagnose whether individual infects rubella virus.
Embodiments of the present invention are described in detail below in conjunction with embodiment, actual conditions are not specified in embodiment
, it carries out according to conventional conditions or manufacturer's recommended conditions.Production business men is not specified in agents useful for same or instrument, for that can lead to
Cross commercially available conventional products.
1 mouse of embodiment is immunized
The people IgM (Sichuan mikey biology new material technology Co., Ltd, lot number 150127) that blood source is extracted uses physiology salt
Water is diluted to 3.0mg/ml, mixes with Freund's complete adjuvant (Sigma companies, article No. SLBF-9338V), is noted with 1ml in equal volume
Emitter emulsification is oil emulsion, until the oil emulsion instilled in water does not disperse to stop emulsifying, by the lotion with 160 μ l/
Dosage four limbs armpit only is subcutaneously applied to BALB/c mouse (Chengdu reaches large Experimental Animal Center, 6 week old female, 2) for the first time
Enhance after 21 days immune and be immunized, takes people IgM mixed in equal volume with incomplete Freund's adjuvant (Sigma companies, article No. SLBM9367V)
It is emulsified after conjunction, immunizing dose is 80 μ l/, and enhancing is immune primary week about later, and tail blood is adopted before being immunized every time, detaches blood
Clearly, potency is measured with indirect elisa method.After 5 times immune, all mice serum potency are more than 1:106, you can for merging.Melt
It closes first 3 days, takes people IgM with normal saline dilution to 3.0mg/ml, then mix tail vein supplementary immunization in equal volume with physiological saline,
Dosage is 80 μ l/.
The preparation of 2 hybridoma cell line of embodiment
The preparation of 2-1 feeder cells
Make feeder cells with normal 10 week old BALB/c mouse peritoneal macrophages.1 day before fusion, BALB/c takes eye
Blood draws neck to put to death, and 0.1% bromogeramine impregnates 1 minute, is transferred to 75% alcohol and impregnates 1 minute, is used under sterile working in super-clean bench
Scissors abdominal cut skin, exposure peritonaeum, with syringe Intraperitoneal injection RPMI1640 basic culture solution 6ml, after taken with dropper
Go out, add 4ml RPMI1640 basic culture solutions and rinse repeatedly, recycle flushing liquor, 1000rpm, centrifugation stays precipitation in 5 minutes, uses
The RPMI1640 culture solutions that 20% newborn bovine serum has been added are resuspended, and adjustment cell concentration is 3.2 × 10596 holes are added in a/ml
Plate, 100 holes μ l/, 37 DEG C, 5%CO2Culture.
The preparation of 2-2 immune spleen cells
Mouse supplementary immunization in embodiment 1 aseptically takes out spleen, is placed in plate respectively after three days,
RPMI1640 basic culture solutions rinse primary, shred, grind, filter after the splenocyte that is disperseed, 1000rpm, centrifugation 5 minutes
Precipitation is stayed to centrifuge, RPMI1640 basic culture solutions are resuspended, and the dilution of 3% acetic acid counts.
The preparation of 2-3 myeloma cell
Murine myeloma cell Sp2/0 (preservation of Sichuan mikey biology new material technology Co., Ltd) is sieved through 8-anaguanine
After choosing, cultivates to exponential phase, take 5 big bottle (75cm2) cell suspension is made, 1000rpm is centrifuged 5 minutes and is stayed precipitation, is used
RPMI1640 basic culture solutions are resuspended, count, by 2.0 × 105The cell concentration of a/ml carries out sub-bottle culture (ordinary circumstance every 1
Replace complete 1640 culture mediums of a 15~30ml within~2 days).
2-4 cell fusions and HAT selection culture hybridomas
Myeloma cell and immune spleen cell are pressed 1:6 ratio mixing, RPMI1640 is used in 50ml conical centrifuge tubes
Basic culture solution is washed 1 time, and 1000rpm is centrifuged 5 minutes and stayed precipitation.By cell mixing, it is slowly added to the PEG4000 of 0.6ml 50%
Fusion, 30ml is added in fusion RPMI1640 basic culture solutions after 1 minute terminate cell fusion.700rpm centrifugations weigh after five minutes
It is suspended from 1640 culture mediums containing 1%HAT and 20% newborn bovine serum, averagely instills 12 set of 96 porocyte culture plates.37 DEG C,
5%CO2Culture, it is full to hole that next day adds 1640 culture mediums containing 1%HAT and 20% newborn bovine serum.5 days later half to change culture
Base partly changes culture medium again after 7 days.
The screening of 2-5 positive cell strains
With 0.06M pH9.6 carbonate buffer solutions dilution people IgM, (Sichuan mikey biology new material technology Co., Ltd criticizes
Number 150127) to 5 μ g/ml, 100 μ l are coated with per hole in 96 hole elisa Plates, for detecting cells and supernatant.It is positioned in refrigerator
2~8 DEG C overnight, are abandoned liquid in hole for second day, ELISA washing lotions board-washing three times, pats dry, with the 0.01M containing 10% calf serum
The PBS of pH7.2,150 holes μ l/, 37 DEG C are closed 2 hours, are patted dry, Vacuum Package is for use.The 9th day after splenocyte fusion, cell is taken
In the detection plate of above-mentioned 96 hole, 37 DEG C are incubated 40 minutes 100 μ l of supernatant, and 8000 times of dilutions are added in ELISA board-washings after machine-washing five times
Horseradish peroxidase label sheep anti-mouse igg (production of Sichuan mikey biology new material technology Co., Ltd) 100 μ L, 37 DEG C incubate
It educates 30 minutes after ibid washing, 100 μ L is added per hole and contain 0.1% (M/V) o-phenylenediamine, 0.1% (V/V) hydrogen peroxide, pH5.0 lemons
Acid phosphoric acid buffer solution, 37 DEG C are incubated 10 minutes, and 50 μ L 2M sulfuric acid solutions are added per hole and terminate reaction, survey 450nm absorption values.With
It is positive control that mice serum, which is diluted to 100 times, when fusion, and 1640 complete culture solutions of RPMI are as negative control, negative control
OD values ＜ 0.2, positive control OD values ＞ 1.8 are that detecting system is effective, are positive when value >=2 sample OD × negative control OD values
Property, otherwise it is feminine gender.Secretory antibody positive cell hole is cloned on 96 well culture plates with limiting dilution assay with 1 cells/well, sieve
Method continuously clone four times on positive Kong Yi are selected, 100% monoclonal is reached, is transferred to 24 holes and continues to cultivate, wait for that cell covers with
It is transferred to when 80% after cell bottle expands culture, sub-bottle passes on when cell covers with cell bottle 80%, and the cell growth of passage is to right
When the number phase, with appropriate serum-free RPMI-1640 culture mediums cell dispersion bottle inner cell, cell suspension is collected in conical centrifuge tube
In, cell suspension volume V is recorded, takes appropriate cell suspension to carry out cell count, obtains cell suspension density (a/ml), remaining
Supernatant is abandoned after 1000rpm centrifugations 5min, the cell number of precipitation is calculated according to cell density and centrifugation precursor, to cell precipitation
It is middle that appropriate frozen stock solution adjustment cell density is added to 4~8 × 106A/ml (takes and carries out counting confirmation in right amount, if cell number is not
In range, then centrifuged again according to cell count total amount, rejoin appropriate frozen stock solution, finally make cell concentration 4~8 ×
106A/ml), it is then sub-packed in sterile cryopreservation tube, every cryopreservation tube refinement cytosol 0.5ml.It is steady that cell fusion obtains 12 plants of energy
Surely the hybridoma cell strain for secreting the anti-human IgM monoclonal antibody antibody of mouse, see the table below 1.Wherein, hybridoma cell strain 9E1-C1-
Antibody secreted by the C8-B3-G8 effect in the IgM antibody for detecting rubella virus infection early stage is optimal, this hybridoma is thin
Born of the same parents' strain is denoted as IgM-5, and China typical culture collection center is deposited on March 8th, 2018, and deposit number is CCTCC NO:
C201847。
Table 1 screens the hybridoma cell strain of the obtained anti-human IgM monoclonal antibody of stably excreting
| Hybridoma | Hybridoma | Hybridoma |
| 1A10-C1-D1-H12-C7 | 3H3-H10-D5-D12-D1 | 9E1-C1-C8-B3-G8 |
| 1D6-E1-C3-B7-F2 | 12F2-A12-C9-D12-D9 | 4F10-H7-C1-C12-D5 |
| 2A3-A5-E2-C12-G10 | 11C10-H7-H6-F8-E5 | 5H7-C1-C9-A8-G9 |
| 2E11-H2-A4-E11-G9 | 10H12-E1-H11-D11-G5 | 8H2-H1-E5-E5-E9 |
The preparation of 3 monoclonal antibody of embodiment
Select the BALB/c mouse of 6~8 weeks health, every mouse peritoneal injection 0.5ml atoleines (Tianjin Ke Miou), 7
Every mouse peritoneal injection 1.6 × 10 after it6A hybridoma.Inoculating cell can generate ascites, close observation after 7~10 days
The health status of animal and sign of ascites as, before waiting for that ascites is as more as possible, and mouse is dying, execution mouse, with dropper by ascites
It sucks in test tube, a mouse can obtain 1~5ml ascites.The ascites centrifuging and taking supernatant of collection takes sample to be put in -20 DEG C of refrigerators and protects
It deposits.Ascites is respectively with after sulfate of ammoniac saturation precipitation, then is purified with Protein A affinity chromatography, and SDS-PAGE detects this antibody and (is denoted as
IgM-Ab5) purity is more than 90%, and electrophoresis result is as shown in Figure 1.
4 Hybridoma Cell Culture supernatant bioactivity of embodiment
With 0.06M pH9.6 carbonate buffer solutions dilution people IgM, (Sichuan mikey biology new material technology Co., Ltd criticizes
Number 150127) to 5 μ g/ml, 100 μ l are coated with per hole in 96 hole elisa Plates.It is positioned in refrigerator and stays overnight for 2~8 DEG C, abandon within second day
Liquid in hole, ELISA board-washings are machine-washed three times, are patted dry, with the PBS of the 0.01M pH7.2 containing 10% calf serum, 150 holes μ l/,
37 DEG C of closings abandon liquid in 2 hours, pat dry, for detecting Hybridoma Cell Culture supernatant, ascites and antibody titer.Hybridoma
The first hole of culture supernatant bioactivity is former times supernatant culture solution, is buffered from the second hole to the 4th hole with the PBS of 0.01M pH7.2
Liquid 10 dilutes step by step again, and the 5th hole to the tenth hole is diluted step by step with 2 times.Mice serum is diluted to 100 when 11-holes are to merge
Make positive control again, negative control is made in the 12nd hole with 1640 complete culture solutions of RPMI, is 100 μ l per hole sample volume.37℃
It is incubated 40 minutes, the sheep anti-mouse igg of 12000 times of diluted horseradish peroxidase labels is added in ELISA board-washings after machine-washing five times
100 μ are added per hole after 37 DEG C of incubations are ibid washed for 30 minutes by (production of Sichuan mikey biology new material technology Co., Ltd) 100 μ L
L contains 0.1% (M/V) o-phenylenediamine, and 0.1% (V/V) hydrogen peroxide, pH5.0 citrate phosphate buffers, 37 DEG C are incubated 10 minutes,
50 μ L 2M sulfuric acid solutions are added per hole and terminate reaction, survey 450nm absorption values.Negative control OD value ＜ 0.2, positive control OD values
＞ 1.8 is that detecting system is effective, on the contrary for feminine gender for the positive when value >=2 OD × negative control OD value.The minimum sun of detected value
Dilution ratio corresponding to property hole is Hybridoma Cell Culture supernatant potency, this Hybridoma Cell Culture supernatant antibody titer is big
In 1:8×103, it is shown in Table 2.
2 culture supernatant potency result of table
| It numbers in enzyme mark hole | 1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9 | 10 | 11 | 12 |
| Extension rate | 1 | 10 | 100 | 1000 | 2000 | 4000 | 8000 | 16000 | 32000 | 64000 | Positive control | Negative control |
| IgM-5 supernatants | 1.91 | 1.92 | 1.58 | 1.28 | 0.79 | 0.59 | 0.25 | 0.04 | 0.04 | 0.04 | 2.35 | 0.04 |
5 titer of ascites of embodiment detects
ELISA detection method is the same as embodiment 4.Dilution process is different, specially：First hole is former times ascites, with 0.01M
The PBS buffer solution of pH7.2 dilutes step by step again from the second hole to seven apertures in the human head 10, is diluted step by step with 2 times from octal to the tenth hole.Inspection
Dilution ratio corresponding to the minimum positive hole of measured value is titer of ascites, and table 3 is titer of ascites, this hybridoma IgM-5 institutes
The titer of ascites of preparation is more than 1:2×106。
3 titer of ascites of table
| It numbers in enzyme mark hole | 1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9 | 10 | 11 | 12 |
| Extension rate | 1 | 10 | 100 | 1000 | 10000 | 100000 | 1000000 | 2000000 | 4000000 | 8000000 | Positive control | Negative control |
| IgM-5 ascites | 2.91 | 2.72 | 2.58 | 2.28 | 1.11 | 0.90 | 0.50 | 0.34 | 0.04 | 0.04 | 2.65 | 0.04 |
6 antibody titer of embodiment detects
First antibody IgM-the Ab5 after purification prepared in embodiment 3 is diluted to the PBS buffer solution of 0.01M pH7.2
1mg/ml, after dilute initial first hole of 100 times of conducts again, since the second hole to the tenth hole make 5 times dilute step by step, 11-holes
Mice serum is diluted to 100 times and makees positive control when merging, and negative control is made in the 12nd hole with PBS, is per hole sample volume
100μl.37 DEG C are incubated 50 minutes, and the sheep of 8000 times of diluted horseradish peroxidase labels is added in ELISA board-washings after machine-washing five times
100 μ L of anti-mouse IgG (production of Sichuan mikey biology new material technology Co., Ltd) are added after 37 DEG C of incubation 1h are ibid washed per hole
100 μ L contain 0.1% (M/V) o-phenylenediamine, and 0.1% (V/V) hydrogen peroxide, pH5.0 citrate phosphate buffers, 37 DEG C are incubated 15
Minute, 50 μ L 2M sulfuric acid solutions are added per hole and terminate reaction, detect 450nm absorption values.Negative control OD value ＜ 0.2 is positive right
It is that detecting system is effective according to OD values ＞ 1.8.Antibody titer criterion：With LOG (dilution) for abscissa, it is with antibody OD values
Ordinate makees curve, and curvilinear equation is y=min+ (max-min)/(1+10^ ((logEC50-x) × Hillslope)), is passed through
Sigmaplot data processing software matched curves, take middle titer=10logEC50.As a result show that this antibody IgM-Ab5 intermediate values are imitated
Valence is 138900.In kind two kinds of commercialization anti-human IgM monoclonal antibody B and C of mouse of control test, by fitting, B is anti-
Titer is that titer is 8793 in 13600, C antibody in body, less than the antibody of the hybridoma secretion of the present invention.Table 4 with
Fig. 2 shows titration results.
4 antibody titer of table detects
7 cross reaction of embodiment measures
With 0.06M pH9.6 carbonate buffer solutions dilution human IgG, (Sichuan mikey biology new material technology Co., Ltd criticizes
Number 140120), mouse IgG (Sichuan mikey biology new material technology Co., Ltd, lot number 140221), rabbit igg (Sichuan mikey biology
New material technology Co., Ltd, lot number 140225) and ox IgG (Sichuan mikey biology new material technology Co., Ltd, lot number
140311) to 2.5 μ g/ml, 100 μ l are coated in 96 hole elisa Plates per hole.It is positioned in refrigerator and stays overnight for 2~8 DEG C, abandon within second day
Liquid in hole, ELISA board-washings machine-wash three times, pat dry, make confining liquid with 0.5% casein of Tris-HCl containing 10mM (7.4),
150 holes μ l/, 37 DEG C of closings are abandoned liquid in 2 hours, are patted dry spare.The anti-human IgM monoclonal antibody IgM-Ab5 of the present invention is used
Same concentrations (0.5mg/ml) are diluted to after HRP labels, then dilute 500 times, 1000 times, 2000 times, 4000 times, 8000 times, are added
Enter in the good ELISA Plate hole of above-mentioned coating, reacted with four kinds of IgG respectively per 50 μ l of hole, 37 DEG C be incubated 30 minutes after ELISA
Board-washing is machine-washed five times, is patted dry, and 100 μ L are added per hole and contain 0.1% (M/V) o-phenylenediamine, 0.1% (V/V) hydrogen peroxide, pH5.0 lemons
Lemon acid phosphoric acid buffer solution, 37 DEG C are incubated 10 minutes, and 50 μ L 2M sulfuric acid solutions are added per hole and terminate reaction, survey 450nm absorption values
(multi-functional readout instrument, manufacturer Thermo, model Varioskan Flas).Following table is the cross reaction measurement result of IgM-Ab5,
There is not cross reaction with four kinds of IgG.
5 cross reaction of table measures
| The IgM-Ab5 dilutions of enzyme mark | 1:500 | 1：1000 | 1：2000 | 1：4000 | 1:8000 |
| People IgM | 1.911 | 1.775 | 1.798 | 1.705 | 1.105 |
| Human IgG | 0.251 | 0.126 | 0.104 | 0.102 | 0.07 |
| Mouse IgG | 0.060 | 0.118 | 0.111 | 0.137 | 0.1 |
| Ox IgG | 0.058 | 0.155 | 0.175 | 0.158 | 0.079 |
The clinical diagnosis of 8 cause of disease of embodiment
(1) prepared by kit
Kit uses enzyme linked immunosorbent assay, utilizes prize law principle.
With the μ of antibody IgM-Ab5 to 1.5 g/ml of the 0.06M pH9.6 carbonate buffer solutions dilution present invention, 96 hole enzyme marks
100 μ l are coated in plate per hole.It is positioned in refrigerator and stays overnight for 2~8 DEG C, abandon within second day liquid in hole, ELISA board-washings machine washing three
It is secondary, it pats dry, with the PBS of the 0.01M pH7.2 containing 10% calf serum, 150 holes μ l/, 37 DEG C of closings abandon liquid in 2 hours, pat dry
It is spare.Sample is diluted 500 times with the PBS buffer solution of 0.01M pH7.2, is added in the good enzyme mark hole of above-mentioned coating, with health
It is negative right with 1000 times of works of PBS buffer solution dilution of the 0.01M pH7.2 containing 10% calf serum after human serum filtration sterilization
According to the PBS buffer solution of the 0.01M pH7.2 containing 10% calf serum after being inactivated with rubella virus IgM antibody positive human serum
Positive control is made in 1000 times of dilution, and setting yin and yang attribute compares each 2 hole and 1 hole of blank, and injection volume is 100 μ l.37 DEG C are incubated 60
Minute, ELISA board-washings are machine-washed five times, and the recombinant rubella virus antigen that horseradish peroxidase (HRP) marks is added, and (Sichuan steps
The production of gram biological material Technology Co., Ltd.) 100 μ L, 37 DEG C are incubated 30 minutes ibid after board-washing, and 100 μ L are added per hole and contain
0.1% (M/V) o-phenylenediamine, 0.1% (V/V) hydrogen peroxide, pH5.0 citrate phosphate buffers, 37 DEG C be incubated 10 minutes, often
Hole is added 50 μ L 2M sulfuric acid solutions and terminates reaction, surveys 450nm absorption value (multi-functional readout instrument, manufacturer Thermo, model
Varioskan Flas).Sample OD values/value >=2.0 feminine gender average control OD are the positive, otherwise are feminine gender.OD values are in 2.1-
It is low concentration region between 2.5, extension rate repetition measurement should be reduced.
(2) sensitivity technique
The detection kit prepared in aforementioned manners examines 200 positives and 200 negative samples respectively.Table 6 is listed
Kit and commercial kit (Zhuhai Special Economic Zone Haitai biology system prepared by the monoclonal antibody IgM-Ab5 of the present invention
Medicine Co., Ltd) comparative experiments, inspection result show detection kit prepared by the monoclonal antibody IgM-Ab5 of the present invention its
Sensitivity and specificity are above commercial kit, and testing result is listed in table 6.
Table 6 is positive to be examined with negative sample
9 stability of embodiment is verified
The stability of monoclonal antibody of the present invention in the presence of a harsh environment by the present invention monoclonal antibody IgM-Ab5 with
It is handled under the conditions of lower：A-20 DEG C of multigelation 2 times；B-20 DEG C of multigelation 3 times；C-20 DEG C of multigelation 4 times；D-20 DEG C repeatedly
Freeze thawing 5 times；E-20 DEG C preserves 7 months；37 DEG C of f thermal accelerations 7 days；37 DEG C of g thermal accelerations 14 days, other conditions are constant, by above-mentioned
It is 100% that method, which is prepared into detection reagent and examines 15 parts of positive reference product and 15 parts of negative reference product, coincidence rate respectively,.Show
This Antibody stability is good, and good using the detection reagent accuracy of this Antibody preparation.It is anti-to choose the higher commercialization of potency
People's IgM monoclonal antibody B (life of Xiamen wave) is prepared into detection reagent after being handled with above-mentioned similarity condition and detects 15 parts of positives respectively
Reference material and 15 parts of negative reference product, beginning after as a result showing it multigelation 5 times or -20 DEG C preserving 7 months repeatedly
Degradation, inspection result and reference material not in full conformity with.Testing result is listed in table 7.
7 stability result of table
It can be seen that the monoclonal antibody stability of the present invention is high, the rubella virus IgM antibody detection reagent being made from it
Very high Stability and dependability can also be kept under the conditions of more rugged environment, this point is in clinical and laboratory applications
In be very valuable progress.
Claims (10)
1. a kind of hybridoma cell strain IgM-5 is preserved in China typical culture collection center, deposit number CCTCC
NO:C201847。
2. a kind of monoclonal antibody, the monoclonal antibody is secreted by hybridoma cell strain described in claim 1.
3. a kind of kit, the kit includes the list described in hybridoma cell strain described in claim 1 or claim 2
Clonal antibody.
4. kit according to claim 3, the kit be colloidal gold immunoassay kit, chemical luminescence reagent kit,
Radioimmunoassay kitss, enzyme linked immunological kit or fluorescence immunoassay kit or the kit are micro-fluid chips；It is preferred that
For enzyme linked immunological kit.
5. the monoclonal antibody described in hybridoma cell strain described in claim 1 or claim 2 is in reagent preparation box
Purposes.
6. purposes according to claim 5, the kit is the kit based on immune detection, it is preferred that the examination
Agent box is colloidal gold immunoassay kit, chemical luminescence reagent kit, radioimmunoassay kitss, enzyme linked immunological kit or fluorescence immunoassay
Kit or the kit are micro-fluid chips；More preferably enzyme linked immunological kit.
7. purposes according to claim 5, the kit is for detecting people IgM.
8. purposes according to claim 7, the people IgM is the people IgM generated at pathogen infection initial stage.
9. purposes according to claim 8, the cause of disease is rubella virus.
10. the monoclonal antibody described in hybridoma cell strain described in claim 1 or claim 2 is being prepared for rubella
Purposes in the kit of poison diagnosis.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201810296837.3A CN108517315B (en) | 2018-03-30 | 2018-03-30 | Anti-human IgM monoclonal antibody, its hybridoma cell strain and application |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201810296837.3A CN108517315B (en) | 2018-03-30 | 2018-03-30 | Anti-human IgM monoclonal antibody, its hybridoma cell strain and application |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN108517315A true CN108517315A (en) | 2018-09-11 |
| CN108517315B CN108517315B (en) | 2019-06-04 |
Family
ID=63431436
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201810296837.3A Active CN108517315B (en) | 2018-03-30 | 2018-03-30 | Anti-human IgM monoclonal antibody, its hybridoma cell strain and application |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN108517315B (en) |
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN109112114A (en) * | 2018-09-18 | 2019-01-01 | 四川迈克生物新材料技术有限公司 | Anti-human igg monoclonal antibody, its hybridoma cell strain and application |
| CN112094352A (en) * | 2020-09-27 | 2020-12-18 | 南京妙迪生物科技有限公司 | anti-IgM monoclonal antibody |
| CN116143931A (en) * | 2021-11-20 | 2023-05-23 | 东莞市朋志生物科技有限公司 | Anti-human IgM antibody and preparation method and application thereof |
Citations (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1831121A (en) * | 2005-09-29 | 2006-09-13 | 张永忠 | Method for structuring hybridoma cell system for anti-human monoclonal antibody of hepatitis B virus and its application |
| CN101072795A (en) * | 2004-12-06 | 2007-11-14 | 麒麟麦酒株式会社 | Human monoclonal antibodies to influenza m2 protein and methods of making and using same |
| CN102127523A (en) * | 2010-11-24 | 2011-07-20 | 江苏省农业科学院 | Hybridoma cell line and application thereof |
| CN102229915A (en) * | 2011-06-22 | 2011-11-02 | 浙江大学 | EV71 virus monoclonal antibody, hybridoma cell line and application |
| CN103923881A (en) * | 2013-08-09 | 2014-07-16 | 北京科兴生物制品有限公司 | Hepatitis A virus monoclonal antibody and its application |
| EP2311879B1 (en) * | 2005-11-24 | 2017-06-21 | Ganymed Pharmaceuticals AG | Monoclonal antibodies against claudin-18 for treatment of cancer |
| BR102015032238A2 (en) * | 2015-12-22 | 2017-06-27 | Universidade Federal De Goiás | HYBRIDOMAS MURINOS PRODUCERS OF HUMAN ANTI-IGM ANTIBODIES |
| BR102015031890A2 (en) * | 2015-12-18 | 2017-06-27 | Universidade Federal De Goiás | HYBRIDOMAS MURINOS PRODUCERS OF HUMAN ANTI-IMMUNOGLOBULIN ANTIBODIES |
-
2018
- 2018-03-30 CN CN201810296837.3A patent/CN108517315B/en active Active
Patent Citations (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101072795A (en) * | 2004-12-06 | 2007-11-14 | 麒麟麦酒株式会社 | Human monoclonal antibodies to influenza m2 protein and methods of making and using same |
| CN1831121A (en) * | 2005-09-29 | 2006-09-13 | 张永忠 | Method for structuring hybridoma cell system for anti-human monoclonal antibody of hepatitis B virus and its application |
| EP2311879B1 (en) * | 2005-11-24 | 2017-06-21 | Ganymed Pharmaceuticals AG | Monoclonal antibodies against claudin-18 for treatment of cancer |
| CN102127523A (en) * | 2010-11-24 | 2011-07-20 | 江苏省农业科学院 | Hybridoma cell line and application thereof |
| CN102229915A (en) * | 2011-06-22 | 2011-11-02 | 浙江大学 | EV71 virus monoclonal antibody, hybridoma cell line and application |
| CN103923881A (en) * | 2013-08-09 | 2014-07-16 | 北京科兴生物制品有限公司 | Hepatitis A virus monoclonal antibody and its application |
| BR102015031890A2 (en) * | 2015-12-18 | 2017-06-27 | Universidade Federal De Goiás | HYBRIDOMAS MURINOS PRODUCERS OF HUMAN ANTI-IMMUNOGLOBULIN ANTIBODIES |
| BR102015032238A2 (en) * | 2015-12-22 | 2017-06-27 | Universidade Federal De Goiás | HYBRIDOMAS MURINOS PRODUCERS OF HUMAN ANTI-IGM ANTIBODIES |
Non-Patent Citations (4)
| Title |
|---|
| BY R. S. TEDDER ET AL.: "The production of monoclonal antibodies to rubella haemagglutinin and their use in antibody-capture assays for rubella-specific IgM", 《J.HYG.CAMB.》 * |
| 李初梅等: "分泌抗风疹病毒McAb杂交瘤细胞株的建立及其初步应用", 《中国医学科学院学报》 * |
| 沈关心等: "抗人IgM单克隆抗体的制备及其特征研究", 《同济医科大学学报》 * |
| 祁鑫等: "风疹病毒单克隆抗体杂交瘤细胞株的建立及应用", 《临床检验杂志》 * |
Cited By (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN109112114A (en) * | 2018-09-18 | 2019-01-01 | 四川迈克生物新材料技术有限公司 | Anti-human igg monoclonal antibody, its hybridoma cell strain and application |
| CN112094352A (en) * | 2020-09-27 | 2020-12-18 | 南京妙迪生物科技有限公司 | anti-IgM monoclonal antibody |
| CN116143931A (en) * | 2021-11-20 | 2023-05-23 | 东莞市朋志生物科技有限公司 | Anti-human IgM antibody and preparation method and application thereof |
| CN116143931B (en) * | 2021-11-20 | 2023-10-31 | 东莞市朋志生物科技有限公司 | Anti-human IgM antibody and preparation method and application thereof |
Also Published As
| Publication number | Publication date |
|---|---|
| CN108517315B (en) | 2019-06-04 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN108517315B (en) | Anti-human IgM monoclonal antibody, its hybridoma cell strain and application | |
| CN107022527A (en) | Hybridoma cell capable of secreting anti-C-reactive protein monoclonal antibody, C-reactive protein detection reagent, and preparation method and application thereof | |
| CN113773382A (en) | SARS-Cov-2 detecting method and reagent kit | |
| CN104357401B (en) | Hybridoma, monoclonal antibody and the application of anti-II types dengue virus NS 1 monoclonal antibody can be secreted | |
| CN108330104B (en) | Anti-human IgM monoclonal antibody, its hybridoma cell strain and application | |
| CN108588031B (en) | Anti-human IgM monoclonal antibody, its hybridoma cell strain and application | |
| CN108588030A (en) | Anti-human IgM monoclonal antibody, its hybridoma cell strain and application | |
| CN109112114A (en) | Anti-human igg monoclonal antibody, its hybridoma cell strain and application | |
| CN108330105A (en) | Anti-human IgM monoclonal antibody, its hybridoma cell strain and application | |
| CN109112113B (en) | Anti-human IgG monoclonal antibody, hybridoma cell strain, kit and application thereof | |
| CN109082413A (en) | Anti-human igg monoclonal antibody, its hybridoma cell strain and application | |
| CN107271674B (en) | A kind of target marker GP73 and detection application method for steatohepatitis detection | |
| CN108517316A (en) | Anti-human IgM monoclonal antibody, its hybridoma cell strain and application | |
| CN108531460A (en) | Anti-human IgM monoclonal antibody, its hybridoma cell strain and application | |
| CN108384761A (en) | Anti-human IgM monoclonal antibody, its hybridoma cell strain and application | |
| CN108330106A (en) | Anti-human IgM monoclonal antibody, its hybridoma cell strain and application | |
| CN109280644A (en) | Anti-human igg monoclonal antibody, its hybridoma cell strain and application | |
| CN110003325A (en) | Hybridoma cell strain and its monoclonal antibody and application generated | |
| CN108531459A (en) | Anti-human IgM monoclonal antibody, its hybridoma cell strain and application | |
| CN111217910B (en) | Monoclonal antibody pair and application thereof in detecting myeloperoxidase protein | |
| Göbel et al. | Production of polyclonal and monoclonal antibodies against hyphae from arbuscular mycorrhizal fungi | |
| CN110218703A (en) | A kind of antigen-specific b cells screening technique and its application in monoclonal antibody preparation | |
| CN109266620A (en) | Anti-human igg monoclonal antibody, its hybridoma cell strain and application | |
| CN107287167A (en) | The hybridoma of the anti-A rotavirus monoclonal antibody of mouse and its monoclonal antibody of secretion can be secreted | |
| CN107828739A (en) | The hybridoma of the anti-bladder chalone C monoclonal antibody of mouse and its monoclonal antibody and purposes of secretion can be secreted |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant | ||
| CP03 | Change of name, title or address | ||
| CP03 | Change of name, title or address |
Address after: 611731 1st floor, block B, building 1, No.8, Anhe 2nd Road, high tech Zone, Chengdu, Sichuan Patentee after: Sichuan ankerei New Material Technology Co.,Ltd. Address before: 611730 floor 1, block B, building 1, No. 8, Anhe Second Road, high tech Zone, Chengdu, Sichuan Patentee before: SICHUAN MACCURA BIOLOGICAL NEW MATERIAL TECHNOLOGY Co.,Ltd. |